☆ 4.1 Article

Low Peripheral B-Cell Counts in Patients With Systemic Rheumatic Diseases Due to Treatment With Belimumab and/or Rituximab Are Associated With Low Antibody Responses to Primary COVID-19 Vaccination

HSS JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Article Rheumatology

Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab

Anthony J. Ocon et al.

Summary: This article reports a longitudinal study on rheumatologic patients receiving rituximab therapy who were administered Evusheld as a preventive measure, and it was confirmed that Evusheld is effective in preventing SARS-CoV-2 infection. The study suggests that using Evusheld as part of a preventive intervention is feasible for high-risk populations.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus

Quentin Moyon et al.

Summary: This study evaluated disease activity and immune responses in SLE patients following BNT162b2 vaccination. MMF and MTX treatments were found to be associated with reduced antibody response, while anti-spike antibody response was positively correlated with baseline immunoglobulin levels, naive B cell frequencies, and SARS-CoV-2-specific T cell response.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

Manuel Francisco Ugarte-Gil et al.

Summary: The severity of COVID-19 outcomes in individuals with SLE is associated with factors such as gender, age, steroid dosage, comorbidities, and the activity of SLE.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Letter Medicine, General & Internal

T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients

Jade Heitz et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2022)

Add to Collection

Article Rheumatology

B Cell Reconstitution Is Strongly Associated With COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Who Received Treatment With Rituximab

Sarah Jinich et al.

Summary: B cell reconstitution level and the time since the last RTX infusion are positively associated with a serologic response to the COVID-19 vaccine.

ARTHRITIS & RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab

Ana-Luisa Stefanski et al.

Summary: Patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) therapy require a minimum of 10 B cells per microliter in the peripheral circulation to mount an appropriate immune response to SARS-CoV-2 vaccination. Functionally relevant B cell depletion results in impaired interferon-gamma secretion by spike-specific CD4 T cells.

ARTHRITIS & RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Ingrid Jyssum et al.

Summary: This study investigates the humoral and cellular immune responses in rheumatoid arthritis patients treated with rituximab after receiving two or three doses of SARS-CoV-2 vaccines. The study finds that some patients do not have serological responses to two doses of the vaccine, but a third dose can enhance the cellular immune response. This is important for understanding the vaccine efficacy in immunocompromised patients.

LANCET RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative

Kathleen M. Andersen et al.

Summary: This study found that the use of immunosuppressive medications in hospitalized COVID-19 patients was associated with a reduced risk of invasive ventilation, but overall no association with in-hospital death. Some medication classes may be associated with an increased risk of death for specific diseases, such as rituximab for rheumatological disease and cancer. Careful medication selection is needed for COVID-19 patients with long-term immunosuppression.

LANCET RHEUMATOLOGY (2022)

Add to Collection

Article Immunology

High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients

Martina Fabris et al.

Summary: This study evaluated the immune response to SARS-CoV-2 mRNA vaccination in patients with complex or rare systemic autoimmune diseases who were previously treated with or under continuous treatment with B-cell-targeted therapies. The results showed that even in the absence of circulating B cells, virus-specific cellular immunity can be induced, indicating that B-cell-targeted therapies do not preclude SARS-CoV-2 vaccination.

JOURNAL OF AUTOIMMUNITY (2022)

Add to Collection

Article Rheumatology

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4

Jeffrey R. Curtis et al.

Summary: This study aims to provide guidance for rheumatology providers on the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases. By summarizing the available literature and data, the study offers recommendations on vaccine efficacy, safety, and the use of immunomodulatory therapies during vaccination.

ARTHRITIS & RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis

Yemil Atisha-Fregoso et al.

Summary: The addition of belimumab to the treatment regimen did not increase adverse events in patients with refractory LN. However, it showed better effects on total and autoreactive naive B cells.

ARTHRITIS & RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

Matthias B. Moor et al.

Summary: The study investigated immune responses to SARS-CoV-2 mRNA vaccines in patients receiving CD20-targeted B-cell-depleting therapies. Results showed blunted immune responses in these patients, indicating potential challenges in vaccination strategies for this population.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jerome Avouac et al.

Summary: Rituximab therapy is associated with more severe COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases, and should be prescribed with caution.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Anja Strangfeld et al.

Summary: Factors associated with COVID-19-related death in people with rheumatic diseases include age, sex, comorbidities, disease activity, and specific medications. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) without increasing glucocorticoid dosages is important, while caution may be required with certain medications such as rituximab and sulfasalazine.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Medical Laboratory Technology

Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers

Christian Irsara et al.

Summary: The clinical performance of the Siemens sCOVG assay was evaluated, with specificity of 99.4% and sensitivity of 90.5%. S1-RBD antibody levels showed good correlation with virus neutralization titers, serving as a surrogate for neutralizing capacity. Levels of S1-RBD IgG increase with age, with significantly higher levels observed in hospitalized COVID-19 patients compared to outpatients.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2021)

Add to Collection

Article Immunology

Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days

Qiu-Yan Xu et al.

Summary: An urgent need for a highly protective vaccine against COVID-19 exists. This study evaluated the response and duration of 5 subsets of anti-SARS-CoV-2 antibodies post-vaccination, and found intense but decaying antibody response with the CoronaVac vaccine, suggesting the need for booster doses in vaccine strategies.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

CD19+IgD+CD27-Naive B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients

Eduard Schulz et al.

Summary: In immunocompromised patients, the number of naive B cells correlates strongly with antibody levels post COVID-19 vaccination, serving as the key predictor for achieving a humoral response comparable to healthy individuals.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Rheumatology

Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study

Jose Maria Alvaro Gracia et al.

Summary: The study found that targeted therapies as a whole do not have a significant impact on the risk of COVID-19 hospitalisation in patients with inflammatory rheumatic diseases, with the exception of rituximab which may increase the risk of hospitalisation, while TNF-i may decrease the odds of hospitalisation. Factors such as age, gender, comorbidities, and COVID-19 symptoms also play a role in patient hospitalisation.

RMD OPEN (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 A Prospective Cohort Study

Parakkal Deepak et al.

Summary: Patients with CID show immune response to mRNA-based SARS-CoV-2 vaccines, but some may have lower antibody levels, especially those receiving glucocorticoids and B-cell depletion therapy. Further studies are needed to confirm these preliminary findings.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Review Rheumatology

Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases

Marcia A. Friedman et al.

Summary: Patients with rheumatic diseases are at increased risk of infectious complications, and disease-modifying antirheumatic drugs can reduce the immunogenicity of common vaccines. Different medications have varying impacts on vaccine immunogenicity, with rituximab having the most substantial effect and Janus kinase and tumour necrosis factor inhibitors decreasing antibody titres. Emerging data suggest that the effect of these medications on the SARS-CoV-2 vaccine immunogenicity is similar to other vaccines, but more research is needed.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer et al.

Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Daniel Mrak et al.

Summary: The study found that RTX-treated patients can develop SARS-CoV-2-specific antibodies after vaccination, but only if peripheral B cells at least partially repopulate. Additionally, more than half of the vaccinated patients developed SARS-CoV-2-specific T cells, which may provide protective effects regardless of humoral immune responses.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

Martin Aringer et al.

ARTHRITIS & RHEUMATOLOGY (2019)

Add to Collection

© Peeref 2019-2024. All rights reserved.